Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.57 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11002313 | 0.84 | PARP1 (0.77) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL9437898 | 0.82 | PARP1 (0.68) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL532134 | 0.81 | PARP1 (1.00) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL28693938 | 0.81 | PARP1 (0.72) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL554735 | 0.81 | PARP1 (0.72) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL351961 | 0.81 | PARP1 (0.72) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL4258386 | 0.81 | PARP1 (0.73) | PARP1NR3C2MMP12DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL3557170 | 0.80 | PARP1 (0.70) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL11006154 | 0.80 | PARP1 (0.70) | PARP1NR3C2MMP12DRD4DRD2 | |
| SCHEMBL11004751 | 0.80 | PARP1 (0.70) | PARP1NR3C2MMP12DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | claimed |
| EP-1556049-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004017974-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | claimed |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1556049-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004017974-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3A | PARP1 1117/4885NR3C2 680/4885MMP12 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.